



Press release – For immediate release
April 10, 2024 – 5:45 pm CEST

Disclosure of total number of voting rights and number of shares in the capital as of March 31st, 2024

Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Sophia Antipolis, France

Total number of shares	18,404,608
Number of real voting rights* (excluding treasury shares**)	18,338,930
Theoretical number of voting rights* (including treasury shares**)	18,296,452

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations



About Median Technologies: Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China, is listed on the Euronext Growth market (ISIN:

FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.medianttechnologies.com

Contacts

Median Technologies Emmanuelle Leygues Head of Corporate Marketing & Financial Communications +33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com	Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59 median@alizerp.com	Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49 24 ghislaine.gasparetto@seitosei-actifin.com
---	--	---